Positive Top-Line Results From Pfizer’S Phase 3 Jade Dare Trial Comparing The Efficacy Of Abrocitinib And Dupilumab For Moderate To Severe Atopic Dermatitis
@MortimerDodd:$Target(TGT)$Target anticipates its operating margin rate will land in a range of around 6% during the back half of 2022. It’s undoubtedly comforting for TGT investors to know the company isn’t overly pessimistic for the remainder of the year.Will Target’s disappointing quarter set TGT stock up for third- and fourth-quarter earnings beats? It’s entirely possible if analysts and investors, given their disappointment today, maintain low expectations for Target.